Strategic assets · Available to partner
Non-dilutive upside outside the 3D printing core.
PharmaTher holds assets outside its 3D printing business that offer potential non-dilutive value. It intends to license, sell, partner or spin them out.
Ketamine ANDA
PharmaTher's FDA-approved ketamine ANDA, sold in December 2025, has the potential to generate more than US$25 million over time (milestones plus a 7-year profit share), subject to the purchaser's commercial performance, with payments expected to begin in Q1 2027.
Available to license, sell, partner or spin out
Four assets ready for the right partner.
KetaVault™
CMC package, INDs, protocols and five orphan designations: ALS, CRPS, IRI organs, seizures and Rett syndrome.
Ketamine microneedle patch
IND-enabling study complete; Phase 1-ready; 40 hours of extended delivery demonstrated.
KetaMist® collaboration
Needle-free, patient-controlled ketamine; collaboration signed July 2026 toward an FDA pathway; 9,000+ patient treatments to date.
Sairiyo Therapeutics Inc.
PharmaTher's 49% interest in a company developing patented, orally bioavailable cepharanthine; US$3.5M U.S. Defense investment (Ebola).
Request a non-confidential summary
Business development and licensing teams can request a summary of any asset.
Request a summaryInvestors
The corporate presentation covers every asset and its potential value.
Download the deck (PDF)Potential ANDA payments depend on the purchaser's commercial performance and are not assured. The licensing, sale, partnering or spin-out of strategic assets may not occur on acceptable terms. KetaMist® is a trademark of its owner and is not FDA-approved. Forward-looking information; see Forward-looking statements.